Immunocore is a commercial-stage biotechnology company that discovered, developed and commercialized the world’s first approved T cell receptor (TCR) therapy. Our mission is to radically improve outcomes for patients with cancer, infectious diseases, and autoimmune diseases, by pioneering and delivering transformative immunomodulating medicines. Built on our proprietary ImmTAX technology, we have a pipeline of investigational bispecific TCR therapies across a broad range of diseases, including multiple types of cancers, HIV, type 1 diabetes, and other autoimmune diseases.